| 发明名称 | Subcutaneous administration of ADAMTS13 | ||
| 摘要 | This invention relates to methods of subcutaneous administration of ADAMTS13 formulations to a treat a disease or condition associated with ADAMTS13 and VWF dysfunction. Furthermore, evidence of the unexpectedly high bioavailability of ADAMTS13 formulations administered subcutaneously is provided herein. | ||
| 申请公布号 | US9611467(B2) | 申请公布日期 | 2017.04.04 |
| 申请号 | US201414210167 | 申请日期 | 2014.03.13 |
| 申请人 | BAXALTA GMBH;BAXALTA INCORPORATED | 发明人 | Kopic Alexandra Nathalie;Höllriegl Werner;Plaimauer Barbara;Rottensteiner Hanspeter;Muchitsch Eva-Maria |
| 分类号 | C12N9/00;C12N9/64;A61K38/48 | 主分类号 | C12N9/00 |
| 代理机构 | Troutman Sanders LLP | 代理人 | Troutman Sanders LLP |
| 主权项 | 1. A method for treating a blood clotting disorder in a mammal, the method comprising subcutaneously administering a therapeutically effective amount of a composition comprising isolated ADAMTS13 to the mammal in need thereof, wherein the therapeutically effective amount of ADAMTS13 is from 20 to 4,000 activity units per kilogram body weight, and the bioavailability of the ADAMTS13 after subcutaneous administration is 50-80% as compared to intravenous administration normalized for the same dose, and thereby treating the blood clotting disorder in the mammal. | ||
| 地址 | CH | ||